DANIA BEACH, FL March 5, 2021—CapsCanada, a Lyfe Group^™ company and leader in capsule technology for over three decades, is pleased to announce the launch of a new liquid-filled hard capsule manufacturing service. CapsCanada’s objective is to support the entire manufacturing process, from formulation and development through full-scale production. In creating this service CapsCanada partnered with one of the leading manufacturers of generic and branded drugs in Canada. Production will be done at a dedicated Health Canada approved facility in Canada that has a full analytical lab, licensing for controlled drugs and substances including narcotics and a choice of blister or bottle packaging.  The facility is also US FDA approved and cGMP compliant for the manufacture and testing of injectables and is currently awaiting US FDA approval for the manufacture and testing of solid oral dosage forms.

We are happy to announce that the Canadian facility in Windsor, Ontario has a new leader in charge. Tom Breshamer has been promoted from Operations Manager to General Manager.

CapsCanada® is pleased to announce the implementation of our registered trademark G-CAPS®.

Given the circumstances of the COVID-19 pandemic, many U.S.-based pharmaceutical manufacturers are suddenly faced with a hard truth: They have a supply chain problem. Specifically, they’re realizing that their existing overseas gelatin capsule supplier may not be able to continue to provide reliable production and delivery.

DANIA BEACH, FL March 10, 2020—CapsCanada, a leading provider of empty capsules for use in the manufacture of pharmaceutical drugs and dietary supplements, announces that it has the production capacity and stock to both continue to meet demand from its existing customers and also help other manufacturers that are affected by supply chain disruptions caused by the Coronavirus outbreak.